2018
Effects of gastroprotectant drugs for the prevention and treatment of peptic ulcer disease and its complications: a meta-analysis of randomised trials
Scally B, Emberson JR, Spata E, Reith C, Davies K, Halls H, Holland L, Wilson K, Bhala N, Hawkey C, Hochberg M, Hunt R, Laine L, Lanas A, Patrono C, Baigent C. Effects of gastroprotectant drugs for the prevention and treatment of peptic ulcer disease and its complications: a meta-analysis of randomised trials. The Lancet Gastroenterology & Hepatology 2018, 3: 231-241. PMID: 29475806, PMCID: PMC5842491, DOI: 10.1016/s2468-1253(18)30037-2.Peer-Reviewed Original ResearchConceptsProton pump inhibitorsUpper gastrointestinal bleedingPeptic ulcer diseaseAcute upper gastrointestinal bleedingGastrointestinal bleedingUlcer diseasePrevention trialsHealing trialsBlood transfusionClinical circumstancesProstaglandin analoguesHistamine-2 receptor antagonistsParticular proton pump inhibitorsNon-steroidal anti-inflammatory drugsEndoscopic ulcer healingDifferent clinical circumstancesUK Medical Research CouncilBritish Heart FoundationDifferent clinical settingsAnti-inflammatory drugsSmall study biasFurther endoscopic interventionMedical Research CouncilLarge protective effectEndoscopic ulcers
2011
Double-Blind Randomized Trials of Single-Tablet Ibuprofen/High-Dose Famotidine vs. Ibuprofen Alone for Reduction of Gastric and Duodenal Ulcers
Laine L, Kivitz AJ, Bello AE, Grahn AY, Schiff MH, Taha AS. Double-Blind Randomized Trials of Single-Tablet Ibuprofen/High-Dose Famotidine vs. Ibuprofen Alone for Reduction of Gastric and Duodenal Ulcers. The American Journal Of Gastroenterology 2011, 107: ajg2011443. PMID: 22186979, PMCID: PMC3321505, DOI: 10.1038/ajg.2011.443.Peer-Reviewed Original ResearchMeSH KeywordsAdministration, OralAdultAgedAged, 80 and overAnti-Inflammatory Agents, Non-SteroidalAnti-Ulcer AgentsChi-Square DistributionDouble-Blind MethodDrug CombinationsDuodenal UlcerEndoscopy, GastrointestinalFamotidineFemaleHumansIbuprofenMaleMiddle AgedProportional Hazards ModelsRisk FactorsStomach UlcerTreatment OutcomeConceptsPrimary end point analysisNon-steroidal anti-inflammatory drugsUpper GI ulcersDuodenal ulcerGI ulcersGastric ulcerEnd-point analysisDaily non-steroidal anti-inflammatory drugsH. pylori stool testDouble-blind randomized trialsMultiple potential risk factorsReduction of gastricSingle-tablet combinationUpper gastrointestinal ulcersDouble-blind trialProportional hazards analysisPotential risk factorsAnti-inflammatory drugsBaseline endoscopyREDUCE studyStudy endoscopyTablets thriceUlcer complicationsStool testRandomized trials
2009
Prescription rates of protective co‐therapy for NSAID users at high GI risk and results of attempts to improve adherence to guidelines
LAINE L, CONNORS L, GRIFFIN MR, CURTIS SP, KAUR A, CANNON CP. Prescription rates of protective co‐therapy for NSAID users at high GI risk and results of attempts to improve adherence to guidelines. Alimentary Pharmacology & Therapeutics 2009, 30: 767-774. PMID: 19594486, DOI: 10.1111/j.1365-2036.2009.04090.x.Peer-Reviewed Original ResearchProton Pump Inhibitors and Bone Fractures?
Laine L. Proton Pump Inhibitors and Bone Fractures? The American Journal Of Gastroenterology 2009, 104: ajg200948. PMID: 19262543, DOI: 10.1038/ajg.2009.48.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsMeSH KeywordsAnti-Ulcer AgentsCausalityDose-Response Relationship, DrugFractures, BoneHip FracturesHumansProton Pump InhibitorsRisk FactorsConceptsProton pump inhibitorsAverage daily dosePPI useHip fractureDaily dosePump inhibitorsReceptor antagonistContinuous proton-pump inhibitorsCase-control studyPotential confounding factorsDose-response relationshipLack of associationManitoba patientsAppropriate indicationsUK patientsCalcium absorptionFracture riskMEDLINE searchBone fracturesHigh dosesConfounding factorsCausal associationDuration responseRelevant articlesLonger duration
2008
Gastric Mucosal Defense and Cytoprotection: Bench to Bedside
Laine L, Takeuchi K, Tarnawski A. Gastric Mucosal Defense and Cytoprotection: Bench to Bedside. Gastroenterology 2008, 135: 41-60. PMID: 18549814, DOI: 10.1053/j.gastro.2008.05.030.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsMeSH KeywordsAnti-Inflammatory Agents, Non-SteroidalAnti-Ulcer AgentsCyclooxygenase InhibitorsGastric MucosaGastritisHumansStomach UlcerConceptsStress-related mucosal diseaseProton pump inhibitorsMucosal defenseGastric mucosal defenseMucosal injuryNoxious factorsNonsteroidal anti-inflammatory drugsCOX-2 selective inhibitorsGeneration of PGsImportant clinical sequelaeUpper gastrointestinal complicationsHigh-risk patientsModern intensive careAbsolute risk reductionInhibition of cyclooxygenaseAnti-inflammatory drugsContinuous blood flowGastrointestinal complicationsClinical sequelaePharmacologic therapyAntisecretory drugsSignificant bleedingAnnual incidenceIntensive careSensory innervation
2006
Effect of frequent dosing of an oral proton pump inhibitor on intragastric pH
PAIS SA, NATHWANI RA, DHAR V, NOWAIN A, LAINE L. Effect of frequent dosing of an oral proton pump inhibitor on intragastric pH. Alimentary Pharmacology & Therapeutics 2006, 23: 1607-1613. PMID: 16696810, DOI: 10.1111/j.1365-2036.2006.02933.x.Peer-Reviewed Original ResearchConceptsProton pump inhibitorsPump inhibitorsOral proton pump inhibitorsDoses of lansoprazoleFrequent oral dosingLansoprazole plasma concentrationHelicobacter pylori statusCYP2C19 statusOral lansoprazolePylori statusOvernight fastOral dosingPlasma concentrationsFrequent dosingHealthy volunteersClot formationTime pointsLansoprazoleMean proportionDosingInhibitorsSubjectsStatusPatientsPeriod
2005
Randomized, double-blind comparison of immediate-release omeprazole oral suspension versus intravenous cimetidine for the prevention of upper gastrointestinal bleeding in critically ill patients
Conrad SA, Gabrielli A, Margolis B, Quartin A, Hata JS, Frank WO, Bagin RG, Rock JA, Hepburn B, Laine L. Randomized, double-blind comparison of immediate-release omeprazole oral suspension versus intravenous cimetidine for the prevention of upper gastrointestinal bleeding in critically ill patients. Critical Care Medicine 2005, 33: 760-765. PMID: 15818102, DOI: 10.1097/01.ccm.0000157751.92249.32.Peer-Reviewed Original ResearchConceptsUpper gastrointestinal bleedingSignificant upper gastrointestinal bleedingGastrointestinal bleedingIll patientsIntravenous cimetidineOmeprazole suspensionMedian gastricChronic Health Evaluation (APACHE II) scoreTrial daysOral suspensionCimetidine treatment groupsDouble-blind trialPrimary end pointDouble-blind comparisonIntensive care unitAdditional risk factorsAcute PhysiologyProtocol populationCimetidine treatmentMedication dosesOrogastric tubeSignificant bleedingCare unitMechanical ventilationGastric aspirates
2003
Bismuth-Based Quadruple Therapy Using a Single Capsule of Bismuth Biskalcitrate, Metronidazole, and Tetracycline Given With Omeprazole Versus Omeprazole, Amoxicillin, and Clarithromycin for Eradication of Helicobacter pylori in Duodenal Ulcer Patients: A Prospective, Randomized, Multicenter, North American Trial
Laine L, Hunt R, El-Zimaity H, Nguyen B, Osato M, Spénard J. Bismuth-Based Quadruple Therapy Using a Single Capsule of Bismuth Biskalcitrate, Metronidazole, and Tetracycline Given With Omeprazole Versus Omeprazole, Amoxicillin, and Clarithromycin for Eradication of Helicobacter pylori in Duodenal Ulcer Patients: A Prospective, Randomized, Multicenter, North American Trial. The American Journal Of Gastroenterology 2003, 98: ajg2003137. PMID: 12650788, DOI: 10.1111/j.1572-0241.2003.t01-1-07288.x.Peer-Reviewed Original ResearchMeSH KeywordsAdministration, OralAdultAgedAmoxicillinAnti-Bacterial AgentsAnti-Ulcer AgentsCapsulesDrug Administration ScheduleDrug CombinationsDrug Therapy, CombinationDuodenal UlcerFemaleHelicobacter InfectionsHelicobacter pyloriHumansMaleMetronidazoleMiddle AgedNorth AmericaOmeprazoleOrganometallic CompoundsTetracyclineTreatment OutcomeConceptsUrea breath testQuadruple therapyDuodenal ulcerBreath testNegative urea breath testTreat eradication ratesH. pylori eradicationActive duodenal ulcerDuodenal ulcer patientsNorth American trialsClarithromycin-resistant strainsActive-controlled trialHelicobacter pylori infectionTreatment of patientsMetronidazole-resistant strainsCapsules q.OAC patientsOAC regimenEradication ratePylori eradicationTriple therapyAdverse eventsUlcer patientsPylori infectionMetronidazole resistance
2002
Helicobacter pylori eradication does not worsen quality of life related to reflux symptoms: a prospective trial
Laine L, Dhir V. Helicobacter pylori eradication does not worsen quality of life related to reflux symptoms: a prospective trial. Alimentary Pharmacology & Therapeutics 2002, 16: 1143-1148. PMID: 12030957, DOI: 10.1046/j.1365-2036.2002.01267.x.Peer-Reviewed Original ResearchMeSH Keywords2-PyridinylmethylsulfinylbenzimidazolesAdultAmoxicillinAnti-Bacterial AgentsAnti-Ulcer AgentsBreath TestsClarithromycinDrug Therapy, CombinationDyspepsiaFemaleGastroesophageal RefluxHelicobacter InfectionsHumansLansoprazoleMaleMiddle AgedOmeprazolePenicillinsProspective StudiesQuality of LifeUreaConceptsGastro-oesophageal reflux diseaseQuality of lifeH. pylori therapyPylori therapyReflux diseaseH. pyloriSymptomatic gastro-oesophageal reflux diseaseHelicobacter pylori eradicationHelicobacter pylori therapyPopulation of patientsEnd of therapyUrea breath testReflux symptomsPylori eradicationTriple therapyProspective trialEndoscopic biopsyPrimary complaintProspective studyLife QuestionnaireBreath testPatientsTherapyMonthsSymptoms
2000
Review article: potential gastrointestinal effects of long‐term acid suppression with proton pump inhibitors
Laine, Ahnen, Mcclain, Solcia, Walsh. Review article: potential gastrointestinal effects of long‐term acid suppression with proton pump inhibitors. Alimentary Pharmacology & Therapeutics 2000, 14: 651-668. PMID: 10848649, DOI: 10.1046/j.1365-2036.2000.00768.x.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsProton pump inhibitor useProton pump inhibitorsLong-term acid suppressionGastric acid suppressionAcid suppressionPump inhibitorsInhibitor useBacterial overgrowthEnteric infectionsGastric adenocarcinomaHigh-dose proton pump inhibitorsCarcinoid formationLong-term proton pump inhibitor useEnterochromaffin-like cell hyperplasiaAdverse effectsChronic acid suppressionImportant clinical sequelaeLong-term protonGastrointestinal adverse effectsMalabsorption of fatVitamin B12 levelsCommon clinical problemH. pylori infectionVitamin B12 concentrationsGastric bacterial overgrowthEndoscopic biopsy requirements for post-treatment diagnosis of Helicobacter pylori
Laine L, Sugg J, Suchower L, Neil G. Endoscopic biopsy requirements for post-treatment diagnosis of Helicobacter pylori. Gastrointestinal Endoscopy 2000, 51: 664-669. PMID: 10840297, DOI: 10.1067/mge.2000.105776.Peer-Reviewed Original ResearchConceptsTriple therapyH pylori infectionBody biopsyAntral biopsiesHistologic examinationPylori infectionBiopsy testsDiagnostic yieldProton pump inhibitor-based triple therapyMulticenter double-blind trialInhibitor-based triple therapyDouble-blind trialPost-treatment sensitivityTriple therapy groupDual antibiotic therapyH pylori statusRapid urease testEndoscopic biopsy testsPost-treatment diagnosisHelicobacter pylori diagnosisPretreatment sensitivityEradication therapyUntreated patientsAntibiotic therapyDual therapy
1998
Twice-daily, 10-day triple therapy with omeprazole, amoxicillin, and clarithromycin for Helicobacter pylori eradication in duodenal ulcer disease: results of three multicenter, double-blind, United States trials
Laine L, Suchower L, Frantz J, Connors A, Neil G. Twice-daily, 10-day triple therapy with omeprazole, amoxicillin, and clarithromycin for Helicobacter pylori eradication in duodenal ulcer disease: results of three multicenter, double-blind, United States trials. The American Journal Of Gastroenterology 1998, 93: ajg1998488. PMID: 9820381, DOI: 10.1111/j.1572-0241.1998.00602.x.Peer-Reviewed Original ResearchConceptsDuodenal ulcer diseaseTriple therapyEradication rateUlcer diseaseH. pylori-infected patientsDaily triple therapyDays of omeprazoleDuodenal ulcer historyProtocol cure ratesProtocol eradication ratesTreat eradication ratesHelicobacter pylori eradicationPylori-infected patientsOAC patientsStudy medicationTreat populationUlcer historyPylori eradicationStudy drugAdverse eventsTwice DailyControlled TrialsDuodenal ulcerCure ratePatientsEffect of proton-pump inhibitor therapy on diagnostic testing for Helicobacter pylori.
Laine L, Estrada R, Trujillo M, Knigge K, Fennerty MB. Effect of proton-pump inhibitor therapy on diagnostic testing for Helicobacter pylori. Annals Of Internal Medicine 1998, 129: 547-50. PMID: 9758575, DOI: 10.7326/0003-4819-129-7-199810010-00007.Peer-Reviewed Original ResearchConceptsUrea breath testProton pump inhibitor therapyBreath test resultsProton pump inhibitorsBreath testInhibitor therapyH. pyloriDiagnostic testingCompletion of therapyProportion of patientsNegative breath test resultH. pylori infectionUrea breath test resultsLansoprazole therapyFalse-negative resultsGastroenterology clinicPylori infectionPatientsHelicobacter pyloriTherapyDuration of conversionPyloriPositive resultsLansoprazoleDaysUS double‐blind, controlled trials of omeprazole and amoxycillin for treatment of Helicobacter pylori
Laine, Johnson, Suchower, Ronca, Hwang, Neil. US double‐blind, controlled trials of omeprazole and amoxycillin for treatment of Helicobacter pylori. Alimentary Pharmacology & Therapeutics 1998, 12: 377-382. PMID: 9690729, DOI: 10.1046/j.1365-2036.1998.00303.x.Peer-Reviewed Original ResearchConceptsH. pylori eradicationDual therapyEradication ratePylori eradicationDuodenal ulcerControlled TrialsHelicobacter pylori eradication ratesOmeprazole/amoxycillinPylori eradication ratesCompletion of therapyActive duodenal ulcerH. pylori diagnosisEndoscopic biopsy testsAmoxycillin resistanceAmoxycillin therapyAdverse eventsAmoxycillinTherapyHelicobacter pyloriOmeprazolePatientsBiopsy testsProtocol analysisUlcersTrialsHelicobacter pylori and peptic ulcer disease
Laine L, Fendrick A. Helicobacter pylori and peptic ulcer disease. Postgraduate Medicine 1998, 103: 231-243. PMID: 9519040, DOI: 10.3810/pgm.1998.03.423.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsMeSH KeywordsAnti-Bacterial AgentsAnti-Ulcer AgentsClarithromycinDrug Therapy, CombinationHelicobacter InfectionsHelicobacter pyloriHumansPeptic UlcerConceptsPeptic ulcer diseaseUlcer diseaseAppropriate antimicrobial therapyPrimary care physiciansCost of careEffective regimensCare physiciansClinical outcomesH pyloriSuccessful treatmentAntimicrobial therapyPatient complianceHelicobacter pyloriImportance of identifyingDiseaseInfectionPyloriTreatmentRegimenRegimensPatientsTherapyPhysiciansCareAccuracy of CLOtest after Helicobacter pylori therapy
Laine L, Suchower L, Johnson E, Ronca P, Neil G. Accuracy of CLOtest after Helicobacter pylori therapy. Gastrointestinal Endoscopy 1998, 47: 250-253. PMID: 9540877, DOI: 10.1016/s0016-5107(98)70321-9.Peer-Reviewed Original ResearchConceptsHelicobacter pylori therapyPylori therapyOmeprazole/amoxicillinCompletion of therapyDouble-blind trialRapid urease testingMore effective therapiesEndoscopic biopsy testsOmeprazole therapyAdditional therapyMost patientsDual therapyUnsuccessful treatmentUrease testingEffective therapyPositive testPatientsH. pyloriTherapyCLOtestBiopsy testsDecreased numberWeeksNegative resultsAmoxicillin
1991
Nosocomial Pneumonia and the Role of Gastric pH A Meta-Analysis
Cook D, Laine L, Guyatt G, Raffin T. Nosocomial Pneumonia and the Role of Gastric pH A Meta-Analysis. CHEST Journal 1991, 100: 7-13. PMID: 1676361, DOI: 10.1378/chest.100.1.7.Peer-Reviewed Original ResearchConceptsStress ulcer prophylaxisUse of sucralfateIncidence of pneumoniaUlcer prophylaxisNosocomial pneumoniaIll patientsGastric pHHistamine-2 receptor antagonistsLarger prospective randomized trialsPercent risk reductionTrial of prophylaxisProspective randomized trialsComputerized bibliographic searchDuplicate independent reviewEffect of antacidIndependent reviewProphylactic therapyRandomized trialsDecreased incidenceControl therapyOdds ratioCommon odds ratioLower incidenceMethodologic deficienciesPneumonia